Evidence map›Paper›PMID 28449585›Full record

ArticleAmerican journal of Alzheimer's disease and other dementias2017

Elevated Plasma Aβ42 in Cognitively Impaired Individuals Taking ACE Inhibitor Antihypertensives.

William T Regenold, Jacob B Blumenthal, David J Loreck, Kristen L Mordecai, Gina Scarinzi, Seshagiri R Doddi, Lawrence Adler

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of Alzheimer's disease and other dementias, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Genome-wide pleiotropy analysis of longitudinal blood pressure and harmonized cognitive performance measures.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Microglial Activation Is Modulated by Captopril:Frontiers in cellular neuroscience · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

William T Regenold1 Department of Psychiatry (Geriatric), University of Maryland School of Medicine, Baltimore, MD, USA.
Jacob B Blumenthal2 GRECC, Baltimore VA Medical Center, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-4193-1536
David J Loreck1 Department of Psychiatry (Geriatric), University of Maryland School of Medicine, Baltimore, MD, USA.
Kristen L Mordecai4 VA Maryland Health Care System, Baltimore, MD, USA.
Gina Scarinzi4 VA Maryland Health Care System, Baltimore, MD, USA.
Seshagiri R Doddi1 Department of Psychiatry (Geriatric), University of Maryland School of Medicine, Baltimore, MD, USA.
Lawrence Adler1 Department of Psychiatry (Geriatric), University of Maryland School of Medicine, Baltimore, MD, USA.
University of Maryland, Baltimore · USVA Maryland Health Care System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background/rationaleAccumulating evidence suggests that the use of angiotensin-converting enzyme inhibitor (ACE-I) medication protects against cognitive decline in the elderly patients. We investigated whether ACE-I use was associated with higher plasma levels of amyloid-β (Aβ), possibly indicating improved Aβ clearance from brain to blood.

methodsWe measured and compared plasma concentrations of Aβ42, Aβ40, and creatinine in cognitively impaired individuals with amnestic mild cognitive impairment, probable Alzheimer's disease (AD) dementia, and mixed probable AD/vascular dementia.

resultsPlasma Aβ42 levels and Aβ42/Aβ40 ratios of participants taking ACE-Is (n = 11) significantly exceeded ( t = 3.1, df = 19, P = .006; U = 24, P = .029, respectively) those not taking ACE-Is (n = 10).

conclusionsThis study is the first to show an association between ACE-I use and increased plasma Aβ42 level and Aβ42/Aβ40 ratio in cognitively impaired individuals. Future investigations should assess whether a possible ACE-I-induced increase in plasma Aβ42 indicates improved Aβ42 clearance from brain that contributes to protection from cognitive decline.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseAmnesiaAmyloid beta-PeptidesAngiotensin-Converting Enzyme InhibitorsCognitive DysfunctionCreatineDementia, VascularFemaleHumansHypertensionMalePeptide FragmentsAmyloid beta-Peptidesamyloid beta-protein (1-40)amyloid beta-protein (1-42)Angiotensin-Converting Enzyme InhibitorsCreatinePeptide FragmentsAlzheimer’s diseaseamyloidangiotensin converting enzyme inhibitorclearancedementiamild cognitive impairment

Identifiers

PMID28449585
PMCPMC10852825
OpenAlexW2608342910

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.